AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Niagen Bioscience, Inc. Common Stock
XNAS · usd
SIC 2833 · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
FIGI BBG001S9LSR3
2.43▼ 0.09 (-3.57%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
2.52
Day's Range
2.42 – 2.50
52-Week Range
2.42 – 7.95
Volume
543.0K
Avg Volume
528.2K
Share Statistics
Shares Outstanding
Employees
117
Exchange
XNAS
Listed
2008-06-24
Share count as of July 30, 2026

Niagen Bioscience, Inc. Common Stock (NAGE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Niagen Bioscience, Inc. Common Stock (NAGE)
What is Niagen Bioscience, Inc. Common Stock's Market Cap?
Niagen Bioscience, Inc. Common Stock's Market Cap is $192.3M, based on as-reported figures from SEC (XBRL) filings.
What is Niagen Bioscience, Inc. Common Stock's Enterprise Value?
Niagen Bioscience, Inc. Common Stock's Enterprise Value is $125.5M, based on as-reported figures from SEC (XBRL) filings.
What is Niagen Bioscience, Inc. Common Stock's Trailing P/E?
Niagen Bioscience, Inc. Common Stock's Trailing P/E is 12.0×, based on as-reported figures from SEC (XBRL) filings.
What is Niagen Bioscience, Inc. Common Stock's Price / Sales?
Niagen Bioscience, Inc. Common Stock's Price / Sales is 1.5×, based on as-reported figures from SEC (XBRL) filings.
What is Niagen Bioscience, Inc. Common Stock's EV / Revenue?
Niagen Bioscience, Inc. Common Stock's EV / Revenue is 1.0×, based on as-reported figures from SEC (XBRL) filings.
What is Niagen Bioscience, Inc. Common Stock's EV / EBITDA?
Niagen Bioscience, Inc. Common Stock's EV / EBITDA is 10.8×, based on as-reported figures from SEC (XBRL) filings.
What is Niagen Bioscience, Inc. Common Stock's Revenue (TTM)?
Niagen Bioscience, Inc. Common Stock's Revenue (TTM) is $129.1M, based on as-reported figures from SEC (XBRL) filings.
What is Niagen Bioscience, Inc. Common Stock's Net Income (TTM)?
Niagen Bioscience, Inc. Common Stock's Net Income (TTM) is $16.0M, based on as-reported figures from SEC (XBRL) filings.
What is Niagen Bioscience, Inc. Common Stock's EBITDA?
Niagen Bioscience, Inc. Common Stock's EBITDA is $11.6M, based on as-reported figures from SEC (XBRL) filings.
What is Niagen Bioscience, Inc. Common Stock's Diluted EPS (TTM)?
Niagen Bioscience, Inc. Common Stock's Diluted EPS (TTM) is 0.20, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · NAGEAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Sales, net
YoY growth-4.3%+3.3%+16.2%+32.9%
Cost of sales
Gross profit
% of revenue64.8%63.5%64.1%64.5%
Operating expenses:
Sales and marketing
Research and development
General and administrative
Total operating expenses
% of revenue62.5%58.5%52.1%52.1%
Operating income
% of revenue2.4%5.0%12.1%12.5%
Nonoperating income:
Interest income, net
Gain on sale of operating segment——
Income before provision for income taxes
Provision for income taxes
Net income
% of revenue3.2%20.1%12.2%13.5%
Net income per share attributable to common stockholders:
Basic (in dollar per share)
Diluted (in dollar per share)